Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$26.98 - $50.17 $6.21 Million - $11.6 Million
-230,297 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$22.85 - $48.44 $1.02 Million - $2.17 Million
-44,703 Reduced 16.26%
230,297 $7.57 Million
Q3 2020

Nov 16, 2020

BUY
$16.05 - $34.91 $4.41 Million - $9.6 Million
275,000 New
275,000 $9.6 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $1B
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Logos Global Management LP Portfolio

Follow Logos Global Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Logos Global Management LP with notifications on news.